What is the recommended application protocol for becaplermin (recombinant human platelet‑derived growth factor‑BB) topical gel in a diabetic foot ulcer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Becaplermin Application Protocol for Diabetic Foot Ulcers

Do not routinely use becaplermin (growth factor therapy) as an adjunct to standard care for diabetic foot ulcers, as the most recent 2024 IWGDF guidelines provide a conditional recommendation against its use. 1

Current Guideline Position

The 2024 IWGDF guidelines explicitly state: "We suggest not using growth factor therapy as an adjunct therapy to standard of care for wound healing in people with diabetes‐related foot ulcers (Conditional; Low)" 1. This represents a shift away from routine use of becaplermin, despite its FDA approval and historical evidence of efficacy.

If Becaplermin Is Used (FDA-Approved Protocol)

Should you decide to use becaplermin despite guideline recommendations, the FDA-approved application protocol is as follows 2:

Dosing Calculation

Calculate gel amount based on ulcer dimensions:

  • For measurements in inches: Length × Width × 0.6 = inches of gel from 15g tube
  • For measurements in centimeters: (Length × Width) ÷ 4 = centimeters of gel from 15g tube

Recalculate weekly or biweekly as ulcer size changes 2.

Application Technique

  1. Squeeze calculated gel length onto clean measuring surface (e.g., wax paper)
  2. Measure with ruler to ensure correct amount
  3. Transfer gel using application aid to cleaned, debrided ulcer
  4. Spread to 1/16 inch thickness over entire ulcer surface
  5. Cover with saline-moistened gauze for approximately 12 hours
  6. Remove dressing after 12 hours, rinse ulcer with saline/water to remove residual gel
  7. Apply moist dressing without gel for remainder of day
  8. Apply once daily until complete healing 2

Treatment Duration and Reassessment

  • Discontinue if ulcer fails to decrease by ≥30% after 10 weeks 2
  • Discontinue if not completely healed by 20 weeks 2
  • Maximum treatment duration: 20 weeks 2

Critical Context: Why Guidelines Recommend Against It

The IWGDF 2024 guidelines downgraded growth factor therapy despite historical RCT evidence showing becaplermin increased healing rates from 36% to 50% (p=0.007) and reduced time to healing by 30% 3, 4, 5. This reflects:

  • Low certainty of evidence overall 1
  • Availability of alternative therapies with better evidence profiles
  • Cost-effectiveness concerns in real-world practice
  • Modest clinical benefit compared to standard care alone

Essential Prerequisites

Becaplermin should only be considered when:

  • Best standard care has failed (sharp debridement, off-loading, infection control, moist wound environment) 1
  • Adequate arterial perfusion exists (TcPO₂ >30 mmHg) 2
  • Ulcer is full-thickness (Stage III-IV) 2
  • Ulcer duration ≥8 weeks 2, 3
  • Active infection is controlled 3, 6

Common Pitfalls

  • Using without adequate debridement: Sharp debridement remains the cornerstone; becaplermin cannot compensate for inadequate wound bed preparation 1
  • Continuing beyond 10 weeks without response: Reassess at 10 weeks; lack of 30% size reduction predicts treatment failure 2
  • Applying to infected ulcers: Control infection first 3
  • Inadequate off-loading: Growth factors cannot overcome mechanical trauma 2, 3

Alternative Approaches with Stronger Evidence

Consider instead:

  • Autologous leucocyte, platelet, and fibrin patch (Conditional; Moderate evidence) 1
  • Placental-derived products (Conditional; Low evidence) 1
  • Sucrose-octasulfate dressing for neuro-ischemic ulcers (Conditional; Moderate evidence) 1

Recent 2026 network meta-analysis confirms placenta-derived products show superior efficacy (OR 7.85) compared to standard care, with better safety profile than becaplermin 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.